BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND PPARG, PPARG1, 5468, ENSG00000132170, PPARG2, NR1C3, HUMPPARG
32 results:

  • 1. pparg is a potential target of Tanshinone IIA in prostate cancer treatment: a combination study of molecular docking and dynamic simulation based on transcriptomic bioinformatics.
    Zhang T; Chen X; Ju X; Yuan J; Zhou J; Zhang Z; Ju G; Xu D
    Eur J Med Res; 2023 Nov; 28(1):487. PubMed ID: 37932808
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Protective effects of iodine on rat prostate inflammation induced by sex hormones and on the DU145 prostate cancer cell line treated with TNF.
    Anguiano B; Álvarez L; Delgado-González E; Ortiz-Martínez Z; Montes de Oca C; Morales G; Aceves C
    Mol Cell Endocrinol; 2023 Jul; 572():111957. PubMed ID: 37192707
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
    Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
    Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell's metabolic crosstalk.
    Altuna-Coy A; Ruiz-Plazas X; Sánchez-Martin S; Ascaso-Til H; Prados-Saavedra M; Alves-Santiago M; Bernal-Escoté X; Segarra-Tomás J; R Chacón M
    BMC Med; 2022 Aug; 20(1):255. PubMed ID: 35978404
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Upregulated pparg2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer.
    Li F; Lu T; Liu D; Zhang C; Zhang Y; Dong F
    Cell Death Dis; 2021 May; 12(6):528. PubMed ID: 34023860
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
    Yan Y; Mao X; Zhang Q; Ye Y; Dai Y; Bao M; Zeng Y; Huang R; Mo Z
    Cancer Biomark; 2021; 31(1):87-96. PubMed ID: 33780364
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer.
    Galbraith LCA; Mui E; Nixon C; Hedley A; Strachan D; MacKay G; Sumpton D; Sansom OJ; Leung HY; Ahmad I
    Oncogene; 2021 Apr; 40(13):2355-2366. PubMed ID: 33654198
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Diet and
    Tran L; Bobe G; Arani G; Zhang Y; Zhang Z; Shannon J; Takata Y
    Nutrients; 2021 Jan; 13(1):. PubMed ID: 33477496
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced prostate cancer: A National Population-Based Study Using Patient-Reported Outcomes.
    Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1196-1203. PubMed ID: 32717261
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Visceral Metastasis: A Prognostic Factor of Survival in Patients with Spinal Metastases.
    Lun DX; Chen NW; Feng JT; Yang XG; Xu ZW; Li F; Hu YC
    Orthop Surg; 2020 Apr; 12(2):552-560. PubMed ID: 32227458
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Recurrent activating mutations of PPARγ associated with luminal bladder tumors.
    Rochel N; Krucker C; Coutos-Thévenot L; Osz J; Zhang R; Guyon E; Zita W; Vanthong S; Hernandez OA; Bourguet M; Badawy KA; Dufour F; Peluso-Iltis C; Heckler-Beji S; Dejaegere A; Kamoun A; de Reyniès A; Neuzillet Y; Rebouissou S; Béraud C; Lang H; Massfelder T; Allory Y; Cianférani S; Stote RH; Radvanyi F; Bernard-Pierrot I
    Nat Commun; 2019 Jan; 10(1):253. PubMed ID: 30651555
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Effect of Lesion Location on prostate cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans.
    Walton E; Yaguchi G; Keeley J; Deebajah M; Menon M; Peabody J; Dabaja A; Alanee S
    J Urol; 2019 Mar; 201(3):503-509. PubMed ID: 30316896
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Lipid pathway deregulation in advanced prostate cancer.
    Galbraith L; Leung HY; Ahmad I
    Pharmacol Res; 2018 May; 131():177-184. PubMed ID: 29466694
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
    Fang E; Zhang X; Wang Q; Wang D
    Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. TR2 and TR4 Orphan Nuclear Receptors: An Overview.
    Lin SJ; Yang DR; Yang G; Lin CY; Chang HC; Li G; Chang C
    Curr Top Dev Biol; 2017; 125():357-373. PubMed ID: 28527578
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Sleeping Beauty screen reveals pparg activation in metastatic prostate cancer.
    Ahmad I; Mui E; Galbraith L; Patel R; Tan EH; Salji M; Rust AG; Repiscak P; Hedley A; Markert E; Loveridge C; van der Weyden L; Edwards J; Sansom OJ; Adams DJ; Leung HY
    Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8290-5. PubMed ID: 27357679
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genetic Variations in Inflammatory Response Genes and Their Association with the Risk of prostate cancer.
    Cui X; Yan H; Ou TW; Jia CS; Wang Q; Xu JJ
    Biomed Res Int; 2015; 2015():674039. PubMed ID: 26788504
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
    Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Association of variants in genes related to the immune response and obesity with BPH in CLUE II.
    Lopez DS; Peskoe SB; Tsilidis KK; Hoffman-Bolton J; Helzlsouer KJ; Isaacs WB; Smith MW; Platz EA
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):353-8. PubMed ID: 25224558
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
    Sun LL; Wu JY; Wu ZY; Shen JH; Xu XE; Chen B; Wang SH; Li EM; Xu LY
    Int J Cancer; 2015 Mar; 136(6):E569-77. PubMed ID: 25220908
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.